Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK Buys BELLUS Health and Gains Access to RRC Treatment, Camlipixant

GSK Buys BELLUS Health and Gains Access to RRC Treatment, Camlipixant

24th April 2023

For $14.75 per share, or $2 billion altogether, GSK will purchase BELLUS, a late-stage biopharmaceutical firm dedicated to enhancing the lives of individuals with refractory chronic cough (RCC).

Camlipixant, which is now in its third stage of testing for the initial treatment of adults with RCC, has been made available to GSK through the purchase.

28 million individuals are believed to have chronic coughs, and 10 million people throughout the world have had RCC for more than 12 consecutive months.

GSK’s Chief Commercial Officer, Luke Miels, explained that those “suffering from severe forms of refractory chronic cough can experience over 900 coughs daily, resulting in quality-of-life issues. Camlipixant, a novel, highly selective P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential.”

GSK’s knowledge in respiratory medications and its top-of-the-line R&D, production, and marketing competencies are complementary to the company’s purchase of BELLUS.

The deal is anticipated to result in sizable sales from 2031 after camlipixant receives clearance for use by regulatory bodies in 2026.

CEO of BELLUS, Roberto Bellini, expressed that the purchase “recognises the value of our highly selective P2X3 antagonist camlipixant and validates the hard work and dedication of all the BELLUS employees in advancing camlipixant to date.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.